| Alternative Name: | Interleukin-1 family member 5, IL-1δ, Interleukin-1δ |
| |
| Concentration: | 1mg/ml after reconstitution. |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Lonza). |
| |
| MW: | ~16kDa |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Source/Host: | Produced in E. coli (aa 2-156). |
| |
| Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| |
| Miscellaneous/General: | IL-1F5, F6, F8 and F9 are members of the family of IL-1 (IL-1α/β, IL-18, IL-33). IL-1F6, IL-1F8 and IL-1F9 activate the NF-κB and MAPK pathways through the IL-Rrp2 and IL-1RAcP receptor complex leading to the production of IL-6 and IL-8. Agonistic activation of the IL-1F6, F8 and F9 is counterbalanced by the inhibitory activity of IL-1F5. These interleukins are mainly expressed in skin keratinocytes and internal epithelial tissues exposed to pathogenic bacteria suggesting a role in immune signalling and inflammation. IL-F5, F6 and F9 as well as the receptor IL-1Rrp2 are increased in psoriasis. |
| |
| Background / Technical Information: | UniProt ID Q9QYY1: Interleukin-1 Family Member 5 (mouse) |
| |